Effects of botulinum toxin type a on quality of life assessed with the WHOQOL-BREF in hemifacial spasm and blepharospasm


GÜRSOY A. E., Ugurad I., Babacan-Yildiz G., KOLUKISA M., Çelebi A.

Neurology Psychiatry and Brain Research, cilt.19, sa.1, ss.12-18, 2013 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 1
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1016/j.npbr.2012.08.001
  • Dergi Adı: Neurology Psychiatry and Brain Research
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.12-18
  • Anahtar Kelimeler: Blepharospasm, Hemifacial spasm, Quality of life, WHOQOL-BREF
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objective: The aim of the study was to compare Quality of life (QoL), depression and anxiety in hemifacial spasm (HFS) and essential blepharospasm (BSP) patients and to analyze the effect of Botulinum Toxin Type A (BtxA) therapy. Materials and methods: Seventy nine consecutive patients with HFS (N = 53, 76% women, mean age 58 years, mean disease duration 98 months) and BSP (N = 26, 62% women, mean age 63 years, mean disease duration 105 months) were included in this study. Quality of Life was measured by the World Health Organization Quality of Life Measurement Instrument Short Form, Turkish Version (WHOQOL-BREF TR), depression by the Hamilton Depression Rating Scale (HDRS) and anxiety by the Hamilton Anxiety Scale (HAS) before the treatment with BtxA and four weeks after the treatment. Results: At baseline, physical health, psychological well-being, and satisfaction with the environment domain scores of WHOQOL-BREF TR, HDRS and HAS scores were not significantly different in two patient groups. Social relationship domain score was found significantly higher in HFS group compared with BLS group. BtxA therapy resulted in a significant improvement of clinical symptom severity, of all domain scores of WHOQOL-BREF TR and of depression and anxiety scores in both HFS and BSP groups. Conclusions: This study demonstrates significant benefit of Botulinum toxin therapy on quality of life, depression and anxiety in patients with BSP and HFS. © 2012 Elsevier GmbH. All rights reserved.